The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with ...

Real-world results may differ from those seen in clinical trials for CAR T-cell therapy and bispecific antibodies for the ...

At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an ...

Anitocabtagene autoleucel may be a promising CAR-T cell therapy option for patients with relapsed/refractory myeloma.